المؤلفون: Desta, Getaye Tessema, Ferede, Yared Andargie, Zewdu, Woretaw Sisay, Adugna, Baye Yrga, Arega, Tilaye, Alemu, Muluken Adela

المصدر: Evidence-based Complementary & Alternative Medicine (eCAM); 12/28/2022, p1-9, 9p, 5 Charts

مصطلحات موضوعية: PHYTOTHERAPY, DRUG efficacy, ANTILIPEMIC agents, METHANOL, ANIMAL experimentation, DIABETES, AMINOGLYCOSIDES, HYPOGLYCEMIC agents, BLOOD sugar, LEAVES, PATIENT safety, MICE, LIPIDS, PHARMACODYNAMICS, EVALUATION

مصطلحات جغرافية: ETHIOPIA

مستخلص: Introduction. Diabetes mellitus (DM) is a chronic endocrine disorder that requires long-term treatment. In Ethiopian traditional medicine practice, plants have been provided with a vital role in fighting human and animal diseases since ancient times. The aqueous extract of Lonchocarpus laxiflorus (L. laxiflorus) leaves has been consumed for treating diabetes mellitus without confirming its safety and efficacy scientifically. This experiment aimed to evaluate the safety and antidiabetic efficacy of the leaf extract of L. laxiflorus in mice models. Methods. The crude extraction was conducted using a cold maceration technique and 80% methanol solvent. Normoglycemic, oral glucose-loaded, and streptozotocin-induced (STZ) diabetic models were employed. Male Swiss albino mice were randomly grouped into five categories(with six mice per group during normoglycemic, oral glucose-loadingtest as a negative control, positive control, and three treatment groups. In STZ-induced diabetic models, the groups include normal and diabetic negative control, diabetic positive control, and three diabetic treatment groups. The negative control groups received vehicles, the positive control received 5 mg/kg glibenclamide, and the treatment groups received the crude extract at 100, 200, and 400 mg/kg doses, respectively. Results. Up to 2000 mg/kg crude extract, neither signs of toxicity nor death were observed. In normoglycemic mice, there was a significant blood glucose reduction at 200 and 400 mg/kg doses starting from the 2^nd h post-administration. The oral glucose load showed a significant antihyperglycemic effect at 200 and 400 mg/kg of the crude extract and glibenclamide. In STZ-induced diabetic models, the 200, 400 mg/kg crude extract, and glibenclamide showed a significant antidiabetic activity and enhancement of a good serum lipid profile. Conclusion. This study confirmed that the leaf of L. laxiflorus was safe and possesses antidiabetic and antidyslipidemic activities. [ABSTRACT FROM AUTHOR]

: Copyright of Evidence-based Complementary & Alternative Medicine (eCAM) is the property of Hindawi Limited and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المؤلفون: Yikna, Berhan Begashaw, Yehualashet, Awgichew Shewasinad

المصدر: Evidence-based Complementary & Alternative Medicine (eCAM); 9/6/2021, p1-24, 24p, 1 Color Photograph, 1 Diagram, 12 Charts, 1 Graph

مصطلحات موضوعية: ONLINE information services, IN vitro studies, MEDICINAL plants, CLINICAL drug trials, IN vivo studies, ANIMAL experimentation, SYSTEMATIC reviews, DIABETES, HYPOGLYCEMIC agents, LEAVES, PLANT extracts, MEDLINE, ANALYTICAL chemistry techniques, PHARMACODYNAMICS

مصطلحات جغرافية: ETHIOPIA

مستخلص: Background. Diabetes mellitus (DM) is a metabolic disorder characterized by a persistent rise in the blood glucose level resulting from defects in cellular insulin function, secretion, or both, which affects millions of people every year. Several drawbacks have been stated with the use of marketed antidiabetic medicines such as drug resistance, adverse effects, toxicities, and even costs. Due to these several limitations, searching for novel antidiabetic medicines from medicinal plants (MPs) is becoming an active area of research. Therefore, MPs are exemplary sources of medicines with many accessible agents being obtained from them because numerous active constituents are isolated from them for direct use as pharmacological medicines or act as lead compounds. This paper was aimed to synthesize a concluding remark using in vitro and in vivo evaluations of extracts and fractions for antidiabetic potentials in Ethiopia, which can be used to direct future clinical trials and related investigations. Method. So as to get data on the different investigations, publications related to experimental evaluations on animal diabetic models in Ethiopia were searched from databases, such as Google Scholar, Web of Science, Medline, PubMed, and Scopus using English key terms. Results. In this paper, about 37 research findings based on data from various areas of Ethiopia published until the end of November 2020 were included. A total of 37 MP species extracts and fractions belonging to 19 families have been revealed in vitro or in vivo for potential antidiabetic activities. Crude extracts were carried out mostly by hydromethanolic whereas fractions were done mostly by chloroform. Leaves were the most commonly experimentally investigated plant part. Among the MP species experimentally studied, the most frequently used to treat DM in Ethiopia were Thymus schimperi Ronniger (Lamiaceae), Moringa stenopetala (Baker f.; Moringaceae), Ajuga remota Benth (Lamiaceae), and Datura stramonium Linn. (Solanaceae). Conclusion. This paper gives aggregate evidences on the potential antidiabetic activities of MPs in Ethiopia. Antidiabetic MPs used in Ethiopia represent crucial input for the future development of novel antidiabetic drugs. To this end, more pharmacological and toxicological investigations need to be considered to prove the safety of constituents obtained from these MPs. Finally, we recommend upcoming research to ensure future success in the clinical study and development of novel medicines for DM treatment from these frequently evaluated MPs. [ABSTRACT FROM AUTHOR]

: Copyright of Evidence-based Complementary & Alternative Medicine (eCAM) is the property of Hindawi Limited and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)